Verrica Pharmaceuticals Inc.
VRCA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $8 | $5 | $9 | $12 |
| % Growth | 47.7% | -43.3% | -24.7% | – |
| Cost of Goods Sold | $3 | $1 | $1 | $0 |
| Gross Profit | $5 | $4 | $8 | $12 |
| % Margin | 63.8% | 85.4% | 92% | 96.1% |
| R&D Expenses | $12 | $20 | $12 | $16 |
| G&A Expenses | $0 | $47 | $17 | $27 |
| SG&A Expenses | $59 | $47 | $17 | $27 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $3 | $0 | -$0 |
| Operating Expenses | $71 | $70 | $30 | $42 |
| Operating Income | -$66 | -$66 | -$21 | -$31 |
| % Margin | -871.3% | -1,283.4% | -235.8% | -257.6% |
| Other Income/Exp. Net | -$11 | -$1 | -$3 | -$4 |
| Pre-Tax Income | -$77 | -$67 | -$24 | -$35 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$77 | -$67 | -$24 | -$35 |
| % Margin | -1,012.1% | -1,307.5% | -271.1% | -292.3% |
| EPS | -14.78 | -14.78 | -7.17 | -12.97 |
| % Growth | 0% | -106.1% | 44.7% | – |
| EPS Diluted | -14.78 | -14.78 | -7.17 | -12.97 |
| Weighted Avg Shares Out | 5 | 5 | 3 | 3 |
| Weighted Avg Shares Out Dil | 5 | 5 | 3 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $3 | $0 | $0 |
| Interest Expense | $9 | $4 | $2 | $4 |
| Depreciation & Amortization | $1 | $1 | $1 | $0 |
| EBITDA | -$66 | -$62 | -$22 | -$30 |
| % Margin | -871% | -1,213.8% | -239.1% | -252.6% |